1 / 15

FCA LIABILITY FOR OFF-LABEL MARKETING

FCA LIABILITY FOR OFF-LABEL MARKETING. Serostim Update. THOMAS M. GREENE Greene & Hoffman November 8, 2005. MAJOR OFF-LABEL CASES. Serostim. Neurontin. Global. $ 704 M. $ 430 M. $ 137 M. $ 240 M. Criminal. $ 567 M. Civil. $ 190 M. FCA LIABILITY.

limei
Télécharger la présentation

FCA LIABILITY FOR OFF-LABEL MARKETING

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FCA LIABILITY FOROFF-LABEL MARKETING Serostim Update THOMAS M. GREENE Greene & Hoffman November 8, 2005

  2. MAJOR OFF-LABEL CASES Serostim Neurontin Global $ 704 M $ 430 M $ 137 M $ 240 M Criminal $ 567 M Civil $ 190 M

  3. FCA LIABILITY • “Court holds that Relator has presented evidence showing that it was foreseeable that Parke-Davis's conduct (including non-fraudulent promotion of off-label Neurontin uses) would ineluctably result in false Medicaid claims.” United States ex rel. Franklin v. Pfizer et al., No. 96-11651-PBS, 2003 U.S. Dist. LEXIS 15754, *15 (D. Mass. Aug. 22, 2003)

  4. SEROSTIM • APPROVED INDICATION Indicated for the treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary.

  5. Erosion of Market • Almost immediately after approval, market for Serostim began to decline steeply due to development of protease inhibitor drugs and combination therapy, which greatly curtailed AIDS wasting syndrome

  6. SEROSTIM • OFF-LABEL USE • Treatment of wasting even when there is no weight loss • Using BIA devices and unapproved software to comparebody cell mass to a theoretical “ideal” reading

  7. MAIN OFF-LABEL MESSAGE • Wasting was being masked by weight gain caused by protease inhibitors • Body cell mass was the true measure of wasting – a patient could have no weight loss or even weight gain, and still be wasting, which would only be detectable by measuring body cell mass

  8. KICKBACKS • Target “thought-leaders” • Offer all-expense-paid trip to Cannes in exchange for 30 new scripts ($630,000)

  9. FDA WARNING LETTERS Total (2004-2005) n = 69 • Manufacturing 10% n = 7 • Research methods 9% n = 6 • Safety 59% n = 41 • Efficacy 33% n = 23 • Broadening indication 26% n = 18

  10. FDA WARNING LETTERS • Only one warning letter relates to off-label statements made at a CME conference • Only one warning letter relates to off-label statements made in a “Dear Doctor” letter • No warning letters relate to off-label statements made in detailing

  11. MARKETING TACTICS WITH POTENTIAL FOR MISUSE • Internet • Clinical Study Results Database • CMEs • Promotional Events • Detailing • Journal Articles • Studies of Off-label Uses • Redefining Product Rationale

  12. CONCLUSIONS • FDA will not be able to monitor what is said directly to doctors • Proof of off-label marketing and kickbacks will continue to hinge on proof of intent • Qui tam cases will continue to be the primary enforcement tool

  13. CONCLUSIONS • Government will continue to seek out whistleblowers by offering substantial rewards

  14. RELATOR SHARE • NEURONTIN: • 1 Relator, $27.3 Million * • SEROSTIM: • 5 Relators, $51.8 Million * Includes statutory award of attorneys fees

  15. THOMAS M. GREENE, ESQ 125 Summer Street, Suite 1410 - Boston, MA 02110 www.greenehoffman.com Phone: (617) 261-0040Fax: (617) 261-3558tgreene@greenehoffman.com

More Related